Hugues Dolgos

Hugues Dolgos serves as the Chief Executive Officer of NMS Group since January 2022, overseeing an integrated R&D organization focused on advancing patient health through innovative drug development, particularly in oncology. In addition to this role, Hugues holds multiple positions within NMS Group's subsidiaries, including Chairperson of the Board for Accelera and NerPharMa, and Chairperson of the Board and CEO for Nerviano Medical Sciences, each dedicated to different aspects of pharmaceutical development and manufacturing. Hugues previously held significant roles at Servier, Merck Group, and Merck Serono, contributing to the advancement of oncology, biopharmacy, and strategic R&D initiatives. Hugues is also involved with advisory positions at CERES BRAIN Therapeutics and Skymab Biotherapeutics, focusing on innovative therapeutic solutions. Hugues’ academic background includes education from Université Paris Cité.